Novo Shortens Its Name as Weight-Loss Race With Lilly Tightens
Novo Nordisk plans to shorten its name to “Novo” and update its company culture under Chief Executive Mike Doustdar. CNBC reported the statement on September 14, 2026.
The company had outlined the shift on September 7 on its own website, describing its next chapter as bringing better health to more people under the Novo name with a revised culture. Novo Nordisk That post framed it as an identity and culture update. The September 14 report is the most recent account.
The news followed a pill launch. Novo Nordisk launched its Wegovy weight-loss pill in Germany on September 1, 2026, Reuters reported. In April, Novo had more than 600,000 prescriptions to protect as Eli Lilly prepared its own new pill that could draw patients away, according to Bloomberg.
On injections, people on a standard dose of Novo’s CagriSema lost 20.2% of body weight after 84 weeks, compared with 23.6% for Eli Lilly’s rival drug, Bloomberg reported in February. Novo shares fell after a Lilly pill helped patients lose weight and control blood sugar about as well as Novo’s injected treatment, according to Bloomberg. Separately, shares dropped after Novo forecast a steep sales decline amid a U.S. push for lower drug prices, Bloomberg reported in February.
In my view, the new name does not change the two factors that moved the shares earlier this year for ordinary savers and pension holders to watch. The first is relative weight loss at 84 weeks — think of it like fuel efficiency for cars, the headline number shoppers compare. With CagriSema at 20.2% against 23.6% for Lilly, Novo must compete on side effects, dose steps, steady supply and pill convenience rather than headline loss. For investors, that shifts the math from one winning injection to a mix of products, where pills can bring different staying power, profit left after making them and deals with insurers.
The broader context here is why the timing draws attention. February tied the sales warning to U.S. price pressure. April tied prescription volume to Lilly’s pill challenge. September puts Novo’s own pill on sale in Germany. The Novo name and revised culture will be judged on three jobs: holding more than 600,000 prescriptions, closing the gap opened by Lilly’s pill data and the CagriSema comparison, and managing what insurers in the United States will pay. A simpler brand can ease talks with patients, doctors and insurers. It cannot replace kept prescriptions and the cash actually collected after discounts.
